Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivermectin MDA for Malaria Control (MATAMAL)
NCT04844905Phase 3Unknown
- Sponsor
- London School of Hygiene & Tropical Medicine
- Start
- May 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of CHILD-IVITAB in malaria, lymphatic filariasis (LF), scabies, soil-transmitted helminthiasis (STH), strongyloidiasis, sponsored by London School of Hygiene & Tropical Medicine. Status: unknown.
02
Drugs
CHILD-IVITAB
03
Conditions
malarialymphatic filariasis (LF)scabiessoil-transmitted helminthiasis (STH)strongyloidiasis
Beyond the preview
Go deeper on NCT04844905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04844905.